
Shares of Biocon BION.NS rise nearly 2%, set to snap 7-day losing run
Biopharma co says unit launches YESINTEK, a biosimilar to Stelara, in the U.S. to treat chronic autoimmune diseases
Analysts avg rating is 'buy'; median PT is 400 rupees vs current price of 327 rupees -LSEG data
BION shed nearly 11% in 7-day losing streak and is down about 12% YTD